Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQUINT: Nivolumab + Ipilimumab vs Chemo + Nivolumab in Squamous NSCLC
NCT03823625Phase 2Unknown
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Sep 2017
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in squamous cell carcinoma of the lung (LSCC) comparing Nivolumab + Ipilimumab with Chemotherapy + Nivolumab (2 arms). Primary endpoint: Overall Survival at 12 months. Status: unknown.
02
Drugs
nivolumabipilimumab
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT03823625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823625.